Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Initiated at Outperform by RBC Capital
Dyne Therapeutics Analyst Ratings
RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45
Form 144 | Dyne Therapeutics(DYN.US) Insider Proposes to Sell 49.25 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 14, $Dyne Therapeutics(DYN.US)$ Insider ForDyne B.V. intends to sell 1.5 million shares of its common stock on Nov 14, with a total market value of approximately $49.25
Dyne Therapeutics Reveals Q3 Results and Trial Updates
